{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:01:29Z","timestamp":1784808089605,"version":"3.55.0"},"reference-count":35,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Multimodal treatment in peritoneal metastases (PM) from colorectal neoplasms may improve overall survival (OS). In this study, we reported our experience in using cytoreductive surgery (CRS) combined with intraperitoneal chemohyperthermia (HIPEC) for the treatment of peritoneal metastases (PM) from colorectal neoplasms. The first aim was to evaluate the overall survival of these patients. Furthermore, using the results of the Prodige 7 Trial and incorporating them with the entropy balance statistical tool, we generated a pseudopopulation on which to test the use of CRS alone. We performed a retrospective analysis based on a prospective database of all 55 patients treated with CRS + HIPEC between March 2004 and January 2023. The median OS was 47 months, with 1-, 3- and 5-year survival rates of 90.8%, 58.7% and 42.7%, respectively. There was no significant difference in the data in the pseudogroup generated with entropy balance. This finding confirms the critical role of complete cytoreduction in achieving the best OS for patients with PM. PCI &gt; 6 seems to be the most important prognostic factor influencing OS. At present, CRS + HIPEC seems to be the therapeutic strategy that guarantees the best results in terms of OS for patients with relatively low PCI and in whom a CCS \u2264 1 can be achieved.<\/jats:p>","DOI":"10.3390\/medicina60071058","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:19:26Z","timestamp":1719461966000},"page":"1058","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Cancer with Peritoneal Metastasis: A Single-Center Cohort Study"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6420-6209","authenticated-orcid":false,"given":"Fabrizio","family":"D\u2019Acapito","sequence":"first","affiliation":[{"name":"General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Via Forlanini 34, 47121 Forl\u00ec, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Framarini","sequence":"additional","affiliation":[{"name":"General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Via Forlanini 34, 47121 Forl\u00ec, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Di","family":"Pietrantonio","sequence":"additional","affiliation":[{"name":"General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Via Forlanini 34, 47121 Forl\u00ec, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Tauceri","sequence":"additional","affiliation":[{"name":"General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Via Forlanini 34, 47121 Forl\u00ec, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4544-8824","authenticated-orcid":false,"given":"Valentina","family":"Zucchini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, Via Zamboni 33, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0977-428X","authenticated-orcid":false,"given":"Eleonora","family":"Pozzi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, Via Zamboni 33, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-9285","authenticated-orcid":false,"given":"Leonardo","family":"Solaini","sequence":"additional","affiliation":[{"name":"General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Via Forlanini 34, 47121 Forl\u00ec, Italy"},{"name":"Department of Medical and Surgical Sciences, University of Bologna, Via Zamboni 33, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4334-5167","authenticated-orcid":false,"given":"Giorgio","family":"Ercolani","sequence":"additional","affiliation":[{"name":"General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Via Forlanini 34, 47121 Forl\u00ec, Italy"},{"name":"Department of Medical and Surgical Sciences, University of Bologna, Via Zamboni 33, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12957-021-02207-4","article-title":"Actual survival after resection of primary colorectal cancer: Results from a prospective multicenter study","volume":"19","author":"Ijzermans","year":"2021","journal-title":"World J. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.sla.0000197702.46394.16","article-title":"Peritoneal carcinomatosis of colorectal origin: Incidence and current treatment strategies","volume":"243","author":"Koppe","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.sla.0000217629.94941.cf","article-title":"Epidemiology and management of liver metastases from colorectal cancer","volume":"244","author":"Manfredi","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00384-018-3091-x","article-title":"Prognostic value of distant metastasis sites and surgery in stage IV colorectal cancer: A population-based study","volume":"33","author":"Luo","year":"2018","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yang, Z., Li, Y., Qin, X., Lv, Z., Wang, H., Wu, D., Yuan, Z., and Wang, H. (2021). Development and Validation of a Prognostic Nomogram for Colorectal Cancer Patients with Synchronous Peritoneal Metastasis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.615321"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1055-3207(03)00044-9","article-title":"Natural history of peritoneal carcinomatosis from nongynecologic malignancies","volume":"12","author":"Glehen","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_9","first-page":"83","article-title":"Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer","volume":"16","author":"Sugarbaker","year":"1989","journal-title":"Semin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1055-3207(03)00048-6","article-title":"Peritonectomy procedures","volume":"12","author":"Sugarbaker","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jso.21061","article-title":"Hyperthermic intraperitoneal chemotherapy: Nomenclature and modalities of perfusion","volume":"98","author":"Glehen","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Cervantes","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_13","first-page":"Xc09","article-title":"Preliminary Experience and Morbidity Analysis of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS\/HIPEC) from a Tertiary Cancer Center in India","volume":"9","author":"Padmanabhan","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/jgo-2020-05","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: Lessons learned from PRODIGE 7","volume":"12","author":"Cashin","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Eftimie, M.A., Potlog, G., and Alexandrescu, S.T. (2023). Surgical Options for Peritoneal Surface Metastases from Digestive Malignancies\u2014A Comprehensive Review. Medicina, 59.","DOI":"10.3390\/medicina59020255"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12957-019-1602-z","article-title":"Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: A single-center cohort study","volume":"17","author":"Solaini","year":"2019","journal-title":"World J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-1-4613-1247-5_15","article-title":"Peritonectomy procedures","volume":"82","author":"Sugarbaker","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1053\/j.seminoncol.2005.06.009","article-title":"A curative approach to peritoneal carcinomatosis from colorectal cancer","volume":"32","author":"Sugarbaker","year":"2005","journal-title":"Semin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/DCR.0000000000001076","article-title":"Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma","volume":"61","author":"Aziz","year":"2018","journal-title":"Dis. Colon. Rectum"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","article-title":"A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7","volume":"36","author":"Quenet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1245\/s10434-014-3798-z","article-title":"The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis","volume":"21","author":"Esquivel","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/jso.23722","article-title":"The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery","volume":"110","author":"Esquivel","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101746","DOI":"10.1016\/j.eclinm.2022.101746","article-title":"Perioperative chemotherapy in colorectal cancer with peritoneal metastases: A global propensity score matched study","volume":"55","author":"Cashin","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1245\/s10434-019-07294-y","article-title":"Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study","volume":"26","author":"Hentzen","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"zrae017","DOI":"10.1093\/bjsopen\/zrae017","article-title":"Hyperthermic intraperitoneal chemotherapy in colorectal cancer","volume":"8","author":"Fisher","year":"2024","journal-title":"BJS Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.surg.2014.06.006","article-title":"High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin","volume":"157","author":"Facy","year":"2015","journal-title":"Surgery"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","article-title":"Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial","volume":"158","year":"2023","journal-title":"JAMA Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102976","DOI":"10.1016\/j.esmoop.2024.102976","article-title":"Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases","volume":"9","author":"Tonello","year":"2024","journal-title":"ESMO Open"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1245\/s10434-021-11045-3","article-title":"Microsatellite and RAS\/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)","volume":"29","author":"Tonello","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5492\/wjccm.v11.i6.375","article-title":"Postoperative complications and critical care management after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy: A systematic review of the literature","volume":"11","author":"Wajekar","year":"2022","journal-title":"World J. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/jso.26969","article-title":"Hyperthermic intraperitoneal chemotherapy does not increase risk of major complication or failure to rescue in cytoreductive surgery","volume":"126","author":"Macfie","year":"2022","journal-title":"J. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e186847","DOI":"10.1001\/jamanetworkopen.2018.6847","article-title":"Morbidity and Mortality Rates Following Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy Compared with Other High-Risk Surgical Oncology Procedures","volume":"2","author":"Foster","year":"2019","journal-title":"JAMA Netw. Open"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/7\/1058\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:06:00Z","timestamp":1760108760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/7\/1058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["medicina60071058"],"URL":"https:\/\/doi.org\/10.3390\/medicina60071058","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]}}}